Background {#s0001}
==========

Overweight is a growing public health problem among HIV-infected people on ART, as also observed in the general populations worldwide.^[@CIT0001]^ The increase in weight among HIV-infected people on ART has been attributed to a state of return to health in which appetite is gained and more food consumed, coupled with low physical activity.^[@CIT0001]^ Weight gain in people on ART has been characterized by dorsocervical fat pad and visceral fat accumulation that may increase the risk of coronary artery disease.^[@CIT0002]^ However, the relatively high percentage of people on ART that are underweight is still a concern.^[@CIT0003]^ Being overweight or underweight may increase the risk of cardiovascular diseases.^[@CIT0004],[@CIT0005]^

Although the developed world is faced with an increasing problem of overweight among HIV-infected people on ART,^[@CIT0006],[@CIT0007]^ the developing world is experiencing a double burden of underweight and overweight.^[@CIT0008],[@CIT0009],[@CIT0010]^ However, the prevalence of underweight and overweight reported from African countries is different,^[@CIT0008],[@CIT0009],[@CIT0010]^ possibly due to differences in ART regimen, duration of ART and socio-economic factors.^[@CIT0002]^

Reports on the burden of underweight and overweight among HIV-infected people from rural parts of South Africa are limited. Up-to-date information on the distribution of weight status among HIV-infected people can guide health providers in designing and improving health promotion programmes. Our goals were (i) to determine the prevalence of underweight and overweight in persons with HIV infection on ART in a rural area in the Limpopo province, one of the poorest provinces in South Africa, and (ii) to identify factors associated with being underweight and overweight in the study population.

Methods {#s0002}
=======

Study design {#s20003}
------------

The study was a descriptive cross-sectional study in which data were collected at one point in time. The study used quantitative methods that generated numerical data. Description of participants' measurements and responses expressed as frequencies and categorised assisted in determining the factors associated with being underweight and overweight using regression models.

Setting {#s20004}
-------

The study was conducted in the three primary health care clinics, Seobi-Dikgale, Sebayeng and Dikgale that are situated within the Dikgale Health and Demographic Surveillance System (HDSS) site. The Dikgale HDSS site consists of 15 villages and is situated about 70 kms to the northeast of Polokwane, the capital city of Limpopo province. Limpopo province is one of the poorest provinces and is situated in the northern part of South Africa.

Sample size calculation {#s20005}
-----------------------

The sample size was obtained using the formula for proportion in a cross-sectional study as $n = \frac{z^{2}p\left( 1–p \right)}{d^{2}}$ where *n* = sample size, *Z* = a statistic for 95% confidence interval is 1.96, *P* = expected proportion, *d* = the maximum permissible difference between sample proportion and population proportion calculated as 20/100 x *P*.^[@CIT0011]^

According to literature, the proportion of overweight in ARV-treated Africans ranges from 27.9% to 46.0%.^[@CIT0009],[@CIT0010]^ Considering an average proportion of 36%, and a corresponding maximum margin of error of 7%, sample size was calculated as follows: Sample size $= \frac{\left( 1.96)^{2}0.36\left( 1–0.36 \right) \right.}{\left( 0.07)^{2} \right.} = 181$ people

A 10% allowance was considered and the expected sample size was 200 people.

Study population and sampling {#s20006}
-----------------------------

The study population comprised of approximately 74 people with HIV infection treated at Seobi-Dikgale clinic, 373 people at Sebayeng and 377 people at Dikgale clinic. Based on these databases and using convenient sampling method, 20 people were recruited from Seobi-Dikgale, 96 people from Sebayeng and 98 from Dikgale clinics. A total of 214 participants were included in the study, and one was excluded due to pregnancy.

Participants aged 15 years and above who came to collect their ART were asked to participate in the study and were only included after written informed consent was obtained through the completion of a consent form approved by the MEDUNSA Ethics committee (-MREC/HS/137/2011:PG). In the case of minors, written informed consent was obtained from their legal guardians. Pregnant women were excluded.

Data collection {#s20007}
---------------

Recruitment and clinical assessment were conducted from September 2013 to March 2014. The WHO stepwise approach to surveillance (STEPS) questionnaire^[@CIT0012]^ was used to obtain information on socio-demographic characteristics, fruit and vegetable intake, physical activity, tobacco use and alcohol consumption. The questionnaire was first used on few people who did not form part of the study. Physical activity and fruit and vegetable intake levels were calculated using WHO analysis programmes guide.^[@CIT0013]^ Physical inactivity was defined as \< 600 metabolic equivalent task-minutes/week (MET-minutes/week), and low fruit and vegetable intake was defined as \< 5 servings/day.^[@CIT0013]^ Data on ART duration were extracted from patients' files.

Anthropometric measurements {#s20008}
---------------------------

Anthropometric measurements were taken following procedures as previously described.^[@CIT0014]^ In brief, weight was measured to the nearest 0.1 kg, using Omron BF 400 (Omron Healthcare, Japan). Height was measured to the nearest 0.1 cm, using a stadiometer. Body mass index (BMI) was calculated as weight (kg)/height (m^2^). BMI is considered as underweight (\< 18.5 kg/m^2^), normal (18.5--24.9 kg/m^2^), overweight (25.0--29.9 kg/m^2^) and obese (≥ 30.0 kg/m^2^).^15^ However, in this study, a BMI of 25.00 kg/m^2^ and above was considered overweight.

Blood collection {#s20009}
----------------

Fasting venous blood samples were drawn by registered nurses. Whole blood was used to measure CD4 counts on the day of collection. Plasma from whole blood was separated through centrifugation at 2000 rpm for 15 minutes and stored at --80^°^C until viral load determination.

Laboratory analysis {#s20010}
-------------------

CD4 lymphocyte count was measured using the Pima Analyser (Inverness Medical, Tokyo, Japan). Viral load determination using the branched deoxyribonucleic acid (DNA) technique (Siemens, South Africa), was performed by Toga Molecular Biology and Pathology Medical Laboratory in South Africa.

Statistical analysis {#s20011}
--------------------

Statistical analysis was performed using Statistical Package for Social Sciences version 23.^[@CIT0016]^ Variables were tested for normality using frequency histograms and line graphs. Data not normally distributed were logarithmically transformed for analysis. ANOVA was used to compare continuous variables and the chi-square test to compare categorical variables among underweight, normal weight and overweight groups. Bivariate logistic regression was used to determine individual influence of socio-demographic factors, HIV and ART variables on underweight and overweight status. Multivariate logistic regression modelling using a forward and backward stepwise approach was used to fit best predictive model and determine independent predictors. Factors significant at *p* ≤ 0.25 in univariate regression analysis and significant interaction terms at *p* \< 0.05 were included in multivariate modelling.

Ethical considerations {#s20012}
----------------------

Ethical approval was obtained from the Ethics Committee of University of Limpopo, Medunsa campus (MREC/HS/137/2011: PG). Permission to conduct the study in the Dikgale HDSS clinics was obtained from the Department of Health-Provincial office and Primary Health Care Capricorn District office.

Results {#s0013}
=======

Socio-demographic and lifestyle characteristics of participants {#s20014}
---------------------------------------------------------------

Of the 214 participants on ART, the majority were women (171 \[79.9%\]). The mean age of participants was 44.8 ± 11.8 years. Based on BMI, a few participants (19 \[8.9%\]) were underweight; 117 (54.7%) had a normal weight; and 78 (36.4%) were overweight. Underweight was three times more prevalent in men (18.6%) than in women (6.4%), whereas overweight was twice as prevalent in women (40.9%) than in men (18.6%). The prevalence of underweight among tobacco users was double the prevalence among non-tobacco users (15.6% vs. 7.1%), whereas the prevalence of overweight was higher among non-tobacco users compared with tobacco users (39.6% vs. 24.4%). However, the differences were not significant. A significantly higher proportion of physically inactive (\< 600MET-minute/week) than physically active (\< 600MET-minute/week) people were overweight (100% vs. 16%, *p* \< 0.05). None of the people whose daily intake was more than 5 servings/day of fruits and vegetables were underweight ([Table 1](#T0001){ref-type="table"}).

###### 

Socio-demographic and lifestyle variables among HIV-infected people on ART by weight status.

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Socio-demographic variable   All participants\   Weight status   Linear association\                   
                               *N* = 214                           *p*                                   
  ---------------------------- ------------------- --------------- --------------------- --------------- -----------------------------------------
  Age (years ± s.d.)           \-                  47.67 ± 14.22   44.23 ± 11.96         44.87 ± 10.60   0.51[\*](#TFN0001){ref-type="table-fn"}

  Age (years)                                                                                             

    \< 30                      11 (5.1)            1 (9.1)         6 (54.5)              4 (36.4)        \-

    30--39                     69 (32.2)           4 (5.8)         43 (62.3)             22 (31.9)       0.88

    40--49                     64 (29.9)           6 (9.4)         31 (48.4)             27 (42.2)       \-

    ≥ 50                       70 (32.7)           8(11.4)         37 (52.9)             25 (35.7)       \-

  Gender                                                                                                  

    Female                     171 (79.9)          11 (6.4)        90 (52.6)             70 (40.9)       0.001

    Male                       43 (20.1)           8 (18.6)        27 (62.8)             8 (18.6)        \-

  Marital status                                                                                          

    Unmarried                  164 (76.6)          15 (9.1)        90 (54.9)             59 (36.0)       0.75

    Married                    50 (23.4)           4 (8.0)         27 (54.0)             19 (38.0)       \-

  Education                                                                                               

    Primary only               114 (53.3)          11 (9.6)        61 (53.5)             42 (36.8)       0.92

    Secondary and above        100 (46.7)          8 (8.0)         56 (56.0)             36 (36.0)       \-

  Employment                                                                                              

    Unemployed                 166 (77.6)          17 (10.2)       87 (52.4              62 (37.3)       0.84

    Employed                   48 (22.4)           2 (4.2)         30 (62.5)             16 (33.3)       \-

  Tobacco use                                                                                             

    Yes                        45 (21.0)           7 (15.6)        27 (60.0)             11 (24.4)       0.02

    No                         169 (79.0)          12 (7.1)        90 (53.3)             67 (39.6)       \-

  Alcohol use                                                                                             

    Yes                        47 (22.0)           4 (8.5)         29 (61.7)             14 (29.8)       0.42

    No                         167 (78.0)          15 (9.0)        88 (52.7)             64 (38.3)       \-

  Pima Analyser (PA)                                                                                      

    \< 600 MET-minutes/week    38 (24.2)           0 (0.0)         0 (0.0)               38 (100)        0.001

    \> 600 MET-minutes/week    119 (75.8)          14 (11.8)       86 (72.2)             19 (16.0)       \-

  Fruit and vegetable intake                                                                              

    \< 5 servings/day          150 (95.5)          14 (9.3)        83 (55.3)             53 (35.3)       0.19

    \> 5 servings/day          7 (4.5)             0 (0.0)         3 (42.9)              4 (57.1)        \-
  ------------------------------------------------------------------------------------------------------------------------------------------------

Data is presented as *n*(%) number (percentage) unless indicated.

Analysis of variance test (ANOVA) *p*-value and chi-square test were used to obtain linear association *p*-value; s.d., standard deviation; ART, antiretroviral therapy; MET-minute/week, metabolic equivalent of task-minutes/week. BMI was considered as underweight (\< 18.5 kg/m^2^), normal (18.5--24.9 kg/m^2^) and overweight (≥ 25.0 kg/m^2^). Data for Pima Analyser (PA) and fruit and vegetable are available for 157 participants.

Clinical characteristics of participants {#s20015}
----------------------------------------

The majority of participants were on efavirenz-based ART (86%) and nevirapine-based ART (12.5%). Only three of the participants (1.5%) were on a lopinavir or ritonavir-based ART regimen. The mean duration of ART in this study was 36 months (range: 1--121 months). Majority of the participants (85%) had an undetectable viral load, and the mean CD4 count was 462 ± 235 cells/mm^[@CIT0003]^.

The prevalence of underweight was lower in people with suppressed viral load (\< 50 copies/ml) compared with people with a viral load of greater than 5000 copies/ml (7.3% vs. 20.0%, *p* \> 0.05), whereas the prevalence of overweight was significantly higher in people with suppressed viral load (\< 50 copies/ml) compared with people with a viral load of greater than 5000 copies/ml (39.9% vs. 0%, *p* \< 0.05). Overweight people tended to have a higher mean CD4 count than the normal weight or underweight people, but levels of significance were not achieved. The levels of high sensitivity C-reactive protein were similarly high in underweight and in overweight people (7.01 mg/l vs. 5.75 mg/l, *p* \> 0.05) but were significantly higher when compared with the levels in people with normal weight ([Table 2](#T0002){ref-type="table"}).

###### 

Clinical variables and conditions among HIV-infected people on ART by weight status.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                        All participants\   Weight status      Linear association\                         
                                         *N* = 214                              *p*                                         
  -------------------------------------- ------------------- ------------------ --------------------- --------------------- ------------------------------------------
  HIV and ART variables                                                                                                     

  CD4 count (mean ± SD)                  \-                  428.6 ± 255.6      432.7 ± 226.5         512.1 ± 237.1         0.06[\*](#TFN0002){ref-type="table-fn"}

  Cell/mm^3^                             73 (35.4)           5 (6.8)            31 (42.5)             37 (50.7)             \-

  \> 500                                 61 (29.6)           5 (8.2)            39 (63.9)             17 (27.9)             0.01

  351--500                               54 (26.2)           7 (13.0)           27 (50.0)             20 (37.0)             \-

  200--350                               18 (8.7)            2 (11.1)           13 (72.2)             3 (16.7)              \-

  \< 200                                                                                                                     

  Viral load ( copies/ml)                                                                                                    

    \< 50                                178 (83.2)          13 (7.3)           94 (52.8)             71 (39.9)             \-

    51--500                              15 (7.0)            3 (20.0)           9 (60.0)              3 (20.0)              0.008

    501--5000                            11 (5.1)            1 (9.1)            6 (54.5)              4 (36.4)              \-

    \> 5000                              10 (4.7)            2 (20.0)           8 (80.0)              0 (0.0)               \-

  ART duration (mean ± SD)                                   38.35 ± 25.71      33.76 ± 24.59         39.07 ± 23.77         0.30[\*](#TFN0002){ref-type="table-fn"}

    \> 60 months                         34 (17.3)           4 (11.8)           18 (52.9)             12 (35.3)             \-

    30--60 months                        69 (35.2)           6 (8.7)            29 (42.0)             34 (49.3)             0.39

    \< 30 months                         93 (47.4)           7 (7.5)            60 (64.5)             26 (28.0)             \-

  ART                                                                                                                        

    EFV-based ART                        172 (86)            17 (9.9)           93 (54.1)             62 (36.0)             0.35

    NVP-based ART                        25 (12.5)           0(0.0)             15 (60.0)             10 (40.0)             \-

    Alluvia-based ART                    3 (1.5)             1 (33.3)           0(0.0)                2 (66.7)              \-

  Clinical measurements and conditions                                                                                      

  Diabetes                                                                                                                  

    Yes                                  10 (4.7)            1 (10.0)           5 (50.0)              4 (40.0)              0.90

    No                                   203 (95.3)          18 (8.9)           111 (54.7)            74 (36.5)             \-

  Hypertension                                                                                                              

    Yes                                  56 (26.2)           3 (5.4)            27 (48.2)             26 (46.4)             0.06

    No                                   158 (73.8)          16 (10.1)          90 (57.0)             52 (32.9)             \-

  HsCRP                                                                                                                     

    Normal level                         71 (34.8)           3 (4.2)            52 (73.2)             16 (22.5)             0.046

    High level                           133 (65.2)          13 (9.8)           59 (44.4)             61 (45.9)             \-

  HsCRP: (mg/l)                                                                                                             

  median(interquartile range)            \-                  7.01(3.22--15.6)   3.38(1.42--7.02)^b^   5.75(3.34--11.1)^b^   0.003[\*](#TFN0002){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

Analysis of variance test (ANOVA) *p*-value and chi-square test were used to obtain linear association *p*-value. ^b^, Indicates significantly different cells. Data are presented as *n*(%) - number (percentage) unless indicated. ART, antiretroviral therapy; BMI, body mass index; BMI was considered as underweight (\< 18.5 kg/m^2^), normal (18.5--24.9 kg/m^2^) and overweight (≥ 25.0 kg/m^2^); HsCRP, high sensitivity C-reactive protein; NVP, nevirapine; EFV, efavirenz.

Predictors of underweight in people on ART {#s20016}
------------------------------------------

In univariate analysis, gender (OR: 3.33, *p* = 0.02) and the interaction of gender and tobacco use (OR: 7.72, *p* = 0.001) were significantly associated with underweight. After controlling for employment, tobacco, fruit and vegetable intake, and viral load in multivariate model, the interaction of gender and tobacco use (OR: 10.87, *p* = 0.003) was an independent predictor of underweight in the final model ([Table 3](#T0003){ref-type="table"}).

###### 

Multivariate logistic regression analysis: predictors of underweight and overweight in HIV-infected people on ART.

  Variables                    Underweight           Overweight                                                                                                                                                
  ---------------------------- --------------------- ------------------------------------------ ------------------- ------- ------------------- ------------------------------------------ ------------------- -------
  Age (years)                                                                                                                                                                                                   
    \< 30                      1 \[Ref\]             \-                                         \-                  \-      1 \[Ref\]           \-                                         \-                  \-
    30--39                     0.68 (0.06--6.08)     0.68                                       \-                  \-      0.82 (0.22--3.09)   0.77                                       \-                  \-
    40--49                     1.03(0.11--9.53)      0.98                                       \-                  \-      1.28 (0.34--4.80)   0.72                                       \-                  \-
    ≥ 50                       1.29 (0.15--11.5)     0.82                                       \-                  \-      0.97 (0.26--3.65)   0.97                                       \-                  \-
  Gender                                                                                                                                                                                                        
    Female                     1 \[Ref\]             \*                                         \-                  \-      1 \[Ref\]           \*                                         1 \[Ref\]           \-
    Male                       3.33 (1.25 - 8.87)    0.02                                       \-                  \-      0.33 (0.14--0.75)   0.009                                      0.29(0.09--0.97)    0.04
  Marital status                                                                                                                                                                                                
    Unmarried                  1 \[Ref\]             \-                                         \-                  \-      1\[Ref\]            \-                                         \-                  \-
    Married                    0.86 (0.27--2.73)     0.80                                       \-                  \-      1.09 (0.57--2.10)   0.95                                       \-                  \-
  Education                                                                                                                                                                                                     
    Primary                    1 \[Ref\]             \-                                         \-                  \-      1\[Ref\]            \-                                         \-                  \-
    Secondary and above        0.81 (0.31--2.11)     0.67                                       \-                  \-      0.96 (0.55--1.69)   0.90                                       \-                  \-
  Employment                                                                                                                                                                                                    
    Unemployed                 1 \[Ref\]             \*                                         \-                  \-      1 \[Ref\]           \-                                         \-                  \-
    Employed                   0.62 (0.29--1.31)     0.21                                       \-                  \-      0.84 (0.43--1.65)   0.61                                       \-                  \-
  Tobacco use                                                                                                                                                                                                   
    No                         1 \[Ref\]             \*                                         \-                  \-      1 \[Ref\]           \-                                         \-                  \-
    Yes                        2.41 (0.89 -- 6.53)   0.08                                       \-                  \-      0.49 (0.23--1.04)   0.06[\*](#TFN0003){ref-type="table-fn"}    \-                  \-
  Alcohol use                                                                                                                                                                                                   
    No                         1 \[Ref\]             \-                                         \-                  \-      1\[ Ref\]           \-                                         \-                  \-
    Yes                        0.94 (0.30--2.99)     0.92                                       \-                  \-      0.68 (0.34--1.37)   0.28                                       \-                  \-
  Physical activity            (1.00--1.00)          0.26                                       \-                  \-      0.99 (0.98--1.00)   0.001[\*](#TFN0003){ref-type="table-fn"}   0.99 (0.99--1.00)   0.001
  Fruit and vegetable intake   0.69 (0.37--1.29)     0.25[\*](#TFN0003){ref-type="table-fn"}    \-                  \-      1.11 (0.89--1.39)   0.37                                       \-                  \-
  CD 4 count (cell/mm^3^)                                                                                                                                                                                       
    \> 500                     1 \[Ref\]             \-                                         \-                  \-      1 \[Ref\]           \*                                         \-                  \-
    351--500                   1.21 (0.34--4.40)     0.77                                       \-                  \-      0.38 (0.18--0.78)   0.008                                      \-                  \-
    201--350                   2.02 (0.61--6.77)     0.25                                       \-                  \-      0.57 (0.28--1.17)   0.13                                       \-                  \-
    \< 200                     1.70 (0.30--9.57)     0.55                                       \-                  \-      0.20 (0.05--0.73)   0.02                                       \-                  \-
  Viral load (copies/ml)                                                                                                                                                                                        
    \< 50                      1 \[Ref\]             \*                                         \-                  \-      1 \[Ref\]           \*                                         \-                  \-
    51--500                    3.17 (0.79--12.68)    0.10                                       \-                  \-      0.38 (0.10--1.38)   0.14                                       \-                  \-
    501--5000                  1.27 (0.15--10.70)    0.83                                       \-                  \-      0.86 (0.24--3.05)   0.82                                       \-                  \-
    \> 5000                    3.17 (0.61--16.51)    0.17                                       \-                  \-                          \-                                         \-                  \-
  ART duration (months)                                                                                                                                                                                         
    \> 60                      1 \[Ref\]             \-                                         \-                  \-      1 \[Ref\]           \*                                         \-                  \-
    30--60                     0.71 (0.19--2.72)     0.62                                       \-                  \-      1.78 (0.76--4.15)   0.18                                       \-                  \-
    \< 30                      0.61 (0.17--2.23)     0.46                                       \-                  \-      0.71 (0.31--1.64)   0.43                                       \-                  \-
  Gender by tobacco use        7.72 (2.46--24.21)    0.001[\*](#TFN0003){ref-type="table-fn"}   10.87(2.30--51.4)   0.003   \-                  \-                                         \-                  \-
  *Classification accuracy*    \-                    \-                                         *93.3*%             \-      \-                  \-                                         *82.7*%             \-

OR, odds ratio; AOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval;

Variables that were included in the multivariate forward and backward stepwise regression model. Variables in final multivariate model are presented with adjusted odds ratio. BMI was considered as underweight (\< 18.5 kg/m^2^), normal (18.5--24.9 kg/m^2^) and overweight (≥ 25.0 kg/m^2^).

Predictors of overweight in people on ART {#s20017}
-----------------------------------------

In univariate analysis, male gender (OR: 0.33, *p* = 0.009) and physical activity (OR: 0.99, *p* = 0.001) significantly associated negatively with overweight. After controlling for tobacco use, CD4 count, viral load and ART duration in multivariate model, male gender (OR: 0.29, *p* = 0.04) and physical activity (OR: 0.99, *p* = 0.001) were independent negative predictors of overweight. Neither ART duration nor viral load or CD4 count was independently associated with overweight in multivariate analysis ([Table 3](#T0003){ref-type="table"}).

Discussion {#s0018}
==========

In this study, 8.9% of the participants were underweight and 36.4% were overweight. Similar to our finding, the prevalence of underweight in the general South African population was recently found to be 7.0%.^[@CIT0017]^ However, the 50.8% prevalence of overweight in the general population^[@CIT0017]^ was higher than the prevalence of overweight observed in our study. The prevalence of underweight and overweight among HIV-infected people on ART reported from rural KwaZulu Natal in South Africa^[@CIT0010]^ are similar to the prevalence observed in our study. However, some low- to middle-income countries are still faced with a higher burden of underweight than overweight ([Table 4](#T0004){ref-type="table"}). Although there is a greater tendency to gain weight while taking ART, weight loss has been observed,^[@CIT0003]^ and therefore, health professionals should monitor patients' weight. An increase in weight among people on ART may be due to a return to good health in which the appetite and caloric intake increases accompanied with a lack of physical activity.^[@CIT0001]^ On the contrary, literature suggests that weight loss during the first 3 months after initiation of ART was associated with symptoms such as difficulty in breathing, nausea, vomiting and oral opportunistic infections.^[@CIT0003]^ Oral opportunistic infections can limit the ability to chew and swallow food leading to loss of appetite and reduced caloric intake. Additionally, poor adherence to ART or drug failure that may result in disease progression may explain a weight loss in people on ART.^[@CIT0003]^ However, our study did not evaluate these symptoms or drug adherence. In the United States^[@CIT0006]^ and the United Kingdom,^[@CIT0007]^ underweight was observed in ≤ 1% and overweight in ≥ 50% of people on ART ([Table 4](#T0004){ref-type="table"}). Although an increasing number of people on ART in developed countries are overweight, in developing countries the co-existence of underweight and overweight among HIV-infected people on ART is a burden that is far from over, despite efforts to eradicate malnutrition. Fears are that the problem of malnutrition (underweight) may be compounded in the future by climate change impacting on agricultural yields and food security.^[@CIT0023]^ Underweight among patients on ART in low- to middle-income countries was shown to contribute to excess early mortality, possibly due to poor immune reconstitution arising from deficient nutritional status.^[@CIT0024]^ Similar to the general population,^[@CIT0004],[@CIT0005]^ overweight in people on ART may increase the risk of developing CVD. The levels of C-reactive protein an inflammatory marker were similar in the underweight group and in the overweight group, as these extreme weight statuses are characterized by inflammation.^[@CIT0025]^ Adipose tissue in overweight individuals may produce proinflammatory cytokine such as interleukin-6, a significant stimulator of C-reactive protein,^[@CIT0026]^ whereas opportunistic infections that may be present in underweight individuals are associated with increased levels of C-reactive protein.^[@CIT0027]^ However, individuals with very low CD4 counts less than 50 cells/µl have been observed to produce a small C-reactive response.^[@CIT0027]^

###### 

Prevalence of underweight and overweight in patients on ART in previous studies.

  Author                                   Study design/Country                  Characteristics of participants   Underweight (%)        Overweight (%)
  ---------------------------------------- ------------------------------------- --------------------------------- ---------------------- -----------------------
  Crum-Ciaflone et al., 2008^[@CIT0006]^   Retrospective/USA                     \- Men                            1                      63
                                                                                 \- 18 years and above                                     
                                                                                 \- Mean ART duration 54 months                            
  McCormick et al., 2014^[@CIT0007]^       A whole year survey/United Kingdom    \- Men and women                  African Black: 0.4     African Black: 77
                                                                                 -18 years and above               F-1; M-0               F- 80.6; M- 70
                                                                                 -Any duration of ART              White Caucasian- 1.7   White Caucasian- 49.2
                                                                                                                   F- 4; M-1              F- 52; M- 48.7
  Wasie et al., 2010^[@CIT0008]^           Cross-sectional/northw est Ethiopia   \- Men and women                  27.8                   4.8
                                                                                 \- 15 years and above                                     
                                                                                 -Any duration of ART                                      
  Mustapha et al., 2011^[@CIT0009]^        Cross- sectional/Nigeria              \- Males and females              24.1                   27.9
                                                                                 \- 18 to 50 years old                                     
                                                                                 \- ART duration ≥ 6 months                                
  Malaza et al., 2012^[@CIT0010]^          Population survey/South Africa        \- Men and women                  7.1                    46
                                                                                 \- Adults                         F-5.5; M-14.4          F-53.1; M-15.5
                                                                                 \- Any duration of ART                                    
  de Senna et al., 2014^[@CIT0018]^        Cross-sectional/Brazil                \- Men and women                  5.5                    37.1
                                                                                 \- 20 years and above             F-7.6; M-3.8           F-42.9; M-32.3
  Frantz & Murenzi, 2013^[@CIT0019]^       Cross-sectional/Rwand a               \- Males and females              F- 4; M- 1.1           F- 46; M-22.1
                                                                                 \- 18 years and above                                     
                                                                                 \- ART duration ≥ 12 months                               
  Gedle et al., 2015^[@CIT0020]^           Cross- sectional/southern Ethiopia    \- Men and women                  25.2                   NA
                                                                                 \- 18 years and above             F-24.9; M-25.9          
                                                                                 \- Any duration of ART                                    
  Anand & Puri, 2014^[@CIT0021]^           Cross- sectional/India                \- Men and women                  40.0                   15.0
                                                                                 \- 21 years and above                                     
                                                                                 \- ART duration ≤ 6 months                                
  Mehta & Khatri, 2013^[@CIT0022]^         Cross- sectional/Nepal                \- Men and women                  24.7                   10.6
                                                                                 \- 19--73 years old                                       
                                                                                 \- ART duration ≥ 3 months                                

F, female; M, male; ART, antiretroviral therapy; NA, not assessed. Underweight (\< 18.5 kg/m^2^), and overweight (≥ 25.0 kg/m^2^).

In this study, overweight was disproportionately more frequent in women than in men, whereas underweight was more frequent in men than in women, as was reported among HIV-infected people in KwaZulu Natal, South Africa^[@CIT0010]^ and in the general population of South Africa.^[@CIT0017]^ In contrast, studies from Brazil^[@CIT0018]^ and Rwanda^[@CIT0019]^ reported a higher prevalence of underweight and overweight in women than men. In Ethiopia, the prevalence of underweight was similar among women and men.^[@CIT0020]^

Physical inactivity^[@CIT0028]^ and low tobacco use^[@CIT0029],[@CIT0030]^ may contribute to the higher prevalence of overweight in women on ART. In addition, studies among black African women from sub-Saharan Africa suggest high target 'ideal' weight, less dissatisfaction with larger body shape and poor awareness of CVD risk as main contributing factors to overweight among HIV-infected women on ART.^[@CIT0007],[@CIT0017],[@CIT0031]^ Black African men on ART on the contrary are less keen to be obese.^[@CIT0007]^

Our study showed that men who used tobacco were more likely to be underweight than men who did not use tobacco. Further analysis to explain this increased risk of underweight among smokers showed that a higher proportion of smokers than non-smokers (11.8% vs. 7.7%) had a viral load greater than 5000 copies/ml and were physically active (100% vs. 95%). Previously, HIV infection was shown to increase the risk of underweight through increased resting energy expenditure,^[@CIT0003]^ whereas the use of tobacco was shown to reduce appetite.^[@CIT0032]^ People on ART who were not physically active were more likely to be overweight than those physically active as was also observed in Rwanda.^[@CIT0019]^ Physical activity may reduce the risk of being overweight^[@CIT0033]^ and has a potential anti-inflammatory effect in people on ART.^[@CIT0034]^

In our study, neither ART duration nor viral load or CD4 count was independently associated with underweight or overweight. Similarly, a study from United States showed that demographics and ART duration could not independently predict the increase of weight in people on ART.^[@CIT0006]^ The relationship between ART duration and BMI is inconsistent.^[@CIT0006],[@CIT0035],[@CIT0036]^ In a longitudinal study, weight gain was observed in a short ART duration (24 weeks) that was followed by weight loss in people treated with stavudine-based ART and maintained weight gain in people treated with tenofovir after 144 weeks.^[@CIT0037]^ Therefore, according to Crum-Cianflone et al. (2008),^[@CIT0006]^ the differences in ART duration may account for variations in this relationship between ART duration and BMI.

According to the WHO strategy to tackle nutritional problems, stakeholders at global, regional and local levels have a mandate to improve diets and physical activity patterns of the population.^[@CIT0038]^ In line with this strategy, South Africa introduced the 'Move for your Health' programme aimed at promoting physical activity. An initiative of major private health insurers the 'Wellness programme' rewards and recognizes those maintaining a healthy weight.^[@CIT0039]^ In addition, programmes such as social grants, the provision of nutritional supplements to children and those on ART are aimed at alleviating undernutrition. However, the impact and effectiveness of these initiatives remains unclear.

Our study is one of a few in South Africa to provide information on the problem of underweight among people on ART in a rural area. The limitations of this study include its cross-sectional design that limits inference. In addition, fruit and vegetable intake, physical activity, tobacco and alcohol use were self-reported, and recall bias may have influenced results. Although our study did not assess the full dietary intake, an assessment of fruit and vegetable intake showed that people in all weight status categories had a lower fruit and vegetable daily intake than recommended. In agreement to this finding, a study conducted in a South African rural and semi-rural area, similar to Dikgale HDSS, found that the intake of fruit and vegetables in that community was low.^[@CIT0040]^ Overcoming this problem particularly in rural areas may therefore remain a challenge, as evidence suggests an association of perceived expense, and low income with low fruit and vegetable intake.^[@CIT0040],[@CIT0041]^ A low level of fruit and vegetable intake may lead to deficiencies in vitamins, predisposing people to a wide range of conditions including CVD, cancers and cataracts^[@CIT0041],[@CIT0042]^ and may accelerate HIV disease progression.^[@CIT0043]^ Most of our participants were older people as the majority of young adults live away from home as temporary migrants for employment reasons.^[@CIT0044]^ Convenient sampling was used to recruit participants. However, recruitment was conducted for a whole month cycle, giving all patients collecting their medication equal opportunity to participate. We also acknowledge the small sample size of our study. Further longitudinal cohort intervention studies that would monitor weight changes in people on ART are needed.

Conclusion {#s0019}
==========

In a rural community in the Limpopo province of South Africa, a high proportion of people on ART were overweight and smaller proportions were underweight. Men who used tobacco had a higher risk of being underweight than non-tobacco users. Female gender and physical inactivity increased the risk of being overweight. There is need to simultaneously address the two extreme weight problems in people on ART through educating this vulnerable population on the benefits of staying away from tobacco use, engaging in physical activity and increasing awareness on CVD risk.
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